HSD17B13 and metabolic dysfunction-associated steatotic liver disease: By using a comparative proteomic approach, we screened differentially expressed LD-associated proteins between histologically normal and biopsy-proven steatotic human liver samples and first reported hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) as a novel liver-enriched, hepatocyte-specific, LD-associated protein in the liver, where it promotes hepatic lipogenesis and the pathogenesis of NAFLD (Su et al., 2014).